Here are some of the reasons why Makary might be the next Cabinet official on the chopping block.

Dr. Marty Makary, the current Commissioner of the Food and Drug Administration (FDA), is reportedly facing significant pressure from within the Trump administration. This pressure stems from multiple reported clashes with President Donald Trump and other White House officials over various issues related to the administration's healthcare agenda. According to anonymous sources within the administration, Makary's position is considered precarious, with some officials suggesting he is on 'thin ice.'

The tensions between Makary and the administration have reportedly escalated in recent weeks, as the White House seeks to reshape its healthcare policies ahead of the upcoming midterm elections. This strategic shift is seen as a critical component of the administration's broader political agenda, aiming to address healthcare concerns that have been prominent among voters. Health and Human Services Secretary Robert F. Kennedy Jr. has reportedly considered reducing Makary's influence within the FDA by delegating significant responsibilities to other officials. This move would effectively diminish Makary's role to that of a figurehead, signaling a lack of confidence in his leadership. The potential ouster of Makary highlights the internal struggles within the administration as it attempts to navigate complex healthcare challenges. The FDA, under Makary's leadership, has been at the forefront of several contentious issues, including drug approvals and regulatory policies, which have occasionally put him at odds with the administration's priorities. While the exact reasons for the reported clashes remain undisclosed, the situation underscores the administration's desire to align its healthcare policies more closely with its political objectives. The outcome of these internal deliberations could have significant implications for the FDA's future direction and its role in shaping national healthcare policy. As the administration continues to evaluate its options, the potential removal of Makary could signal a broader shift in the FDA's approach to regulatory oversight and its engagement with the healthcare industry. The coming weeks will be critical in determining whether Makary will retain his position or if the administration will opt for new leadership to steer its healthcare agenda.